JMJuanfen Mo

Juanfen Mo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juanfen Mo has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Chenxi Cao

    The Department of Oncology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People’s Republic of China

    1 shared publication
  • Jiayuan Wu

    The Key Laboratory, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People’s Republic of China

    1 shared publication
  • Jun Zhang

    The Department of Thoracic Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People’s Republic of China

    1 shared publication
  • Yi Bao

    The Key Laboratory, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China

    1 shared publication
  • YuXuan Zhang

    The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310000, People’s Republic of China

    1 shared publication
  • Yuhong Shen

    Transfusion Center, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    The Study of PIK3CA Hotspot Mutations and Co-Occurring with EGFR, KRAS, and TP53 Mutations in Non-Small Cell Lung Cancer

    by YuXuan Zhang, Yuhong Shen, Jiayuan Wu, Jun Zhang, Chenxi Cao, Juanfen Mo, Yi Bao

    Objective: PIK3CA-mutant non-small-cell lung cancer (NSCLC) is associated with other genetic mutations and may influence treatment strategies and clinical outcomes. We aimed to characterize PIK3CA mutations co-occurring with several major driver mutations using data from published cohorts and our medical center. Materials and Methods: We analyzed NSCLC patients harboring PIK3CA mutations from The Cancer Genome Atlas (TCGA) and Memorial Sloan Kettering (MSK) databases and retrospectively identified NSCLC patients with PIK3CA-mutants at a single medical center from our electronic records. The Log rank test was used to determine the association between PIK3CA mutations and overall survival (OS) in NSCLC patients. Results: Common hotspot mutations in PIK3CA were found in exon 9 (c.1633G > A, E545K, and c.1624G > A, E542K) and exon 20 (c.3140A > G, H1047R) in all cohorts. Co-occurring mutations of PIK3CA with EGFR, KRAS, and TP53 have been frequently observed in patients with NSCLC, with different percentages in these datasets generated by different background. PIK3CA mutations were observed to be significantly associated with poor OS in lung adenocarcinomas patients in the MSKCC cohort (hazard ratio [HR] = 0.519, 95% confidence interval [CI] = 0.301– 0.896; P < 0.05). Conclusion: PIK3CA co-occurring mutations in other genes may represent distinct subsets of NSCLC. Further elucidation of the roles of PIK3CA hotspot mutations combined with other driver mutations, including EGFR and KRAS, is needed to guide effective treatment in patients with advanced NSCLC.